Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients.

导出 OA

翻译打印收藏纠错

作者： Mayte,Delgado-Ureña ^[1] ; Francisco G,Ortega ^[2] ; Diego,de Miguel-Pérez ^[2] ; Alba,Rodriguez-Martínez ^[3] ; Jose L,García-Puche ^[1] ; Hugh,Ilyine ^[2] ; Jose A,Lorente ^[3] ; Jose,Exposito-Hernandez ^[4] ; M Carmen,Garrido-Navas ^[5] ; Miguel,Delgado-Ramirez ^[1] ; M José,Serrano ^[2]

作者单位： Integral Oncology Division, Clinical University Hospital, Av. Dr. Olóriz 16, 18012, Granada, Spain. ^[1] Liquid Biopsy and Metastasis Research Group, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government PTS, Granada, Avenida de la Ilustración, 114, 18016, Granada, Spain. ^[2] Laboratory of Genetic Identification, Legal Medicine and Toxicology Department, Faculty of Medicine, University of Granada, Avenida de la Investigación, 11, 18071, Granada, Spain. ^[3] DestiNA Genomics Ltd, 7-11 Melville St, Edinburgh, EH3 7PE, UK. ^[4] Division of Preventive Medicine and Public Health, CIBERESP, University of Jaen, Campus de las Lagunillas, 23072, Jaén, Spain. ^[5] Integral Oncology Division, Clinical University Hospital, Av. Dr. Olóriz 16, 18012, Granada, Spain. mjose.serrano@genyo.es. ^[6] Liquid Biopsy and Metastasis Research Group, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government PTS, Granada, Avenida de la Ilustración, 114, 18016, Granada, Spain. mjose.serrano@genyo.es. ^[7]

关键词 Bevacizumab Circulating tumor cells CyCAR Metastatic colorectal cancer Prognosis RECIST